21.02.2024 14:57:30

Vaccinex Enters Antibody Discovery Agreements Incorporating ActivMAb Drug Discovery Platform

(RTTNews) - Vaccinex, Inc. (VCNX) has entered into eight new antibody discovery agreements integrating use of its ActivMAb platform to select antibodies against difficult-to-drug transmembrane protein targets. The company said, within the last 3 months, it has entered into new antibody discovery agreements for complex targets with 3 major pharma and biotech companies as well as 5 strategic relationships with other antibody service providers.

ActivMAb is an antibody discovery platform developed by Vaccinex with unique capabilities for multi-pass membrane targets such as G-protein-coupled receptors. The ActivMAb technology has multiple applications including: complex membrane antigen expression and presentation, antibody and antigen discovery, directed evolution and protein optimization.

Shares of Vaccinex are up 18% in pre-market trade on Wednesday.

For More Such Health News, visit rttnews.com.

Nachrichten zu Vaccinex Inc Registered Shsmehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Vaccinex Inc Registered Shsmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!